According to Benzinga Pro, BioNTech's peer group average for short interest as a percentage of float is 5.26%, which means ...

J.P. Morgan analyst Jessica Fye maintained a Buy rating on Ascendis Pharma (ASND – Research Report) today and set a price target of $167.00.

In a report released on January 27, Jessica Fye from J.P. Morgan maintained a Buy rating on Intra-Cellular Therapies (ITCI – Research Report), ...

The same mRNA technology behind COVID-19 vaccines is now being used in the fight against cancer, and the University of ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

How did we get here? February marks five years since Brexit became official. Here are some key developments since the EU-UK ...

Investing.com - Healthcare and vaccine stocks are likely to be in the spotlight on Wednesday as Robert F. Kennedy Jr., U.S. President Donald Trump's pick to run the Department of Health and Human ...

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

Leading vaccine makers are under investor scrutiny as Robert F. Kennedy Jr., a notable vaccine skeptic and President Donald Trump’s nominee to lead the Department of Health and Human Services (HHS), ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...

The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer, rise in biomarker testing rates, the ...